Published by Coherent Market Insights
Posted on September 17, 2021
4 min readLast updated: February 5, 2026
The PTA Balloon Catheter market is set to reach $2,038 million by 2025, driven by the prevalence of cardiovascular and urological diseases.
Global PTA Balloon Catheter Market
PTA stands for ‘percutaneous transluminal angioplasty’. The PTA balloon catheter has an inflatable ‘balloon’ at its tip, which is generally used during a minimally invasive catheterization procedure. This procedure is used to enlarge the narrowed vessel opening. The deflated balloon is positioned at the narrowed space and inflated for the short period of time and deflated again to be removed. PTA balloons come in various sizes, lengths, and shapes, depending on the anatomy they are intended to treat. PTA balloon catheters can be used in two ways for the treatment of peripheral vascular lesions. One way is to expand the lumen of an obstructed blood vessel. This method is referred to as the ‘plain-old balloon angioplasty’ (POBA). The second use is for expanding stents for the treatment of vascular blockages.
The global PTA balloon catheter market was evaluated at US$ 1,127.7 million in 2017, and is expected to record a staggering 6.8% CAGR over the forecast period (2018-2026).
Request For Sample Copy of Report: https://www.coherentmarketinsights.com/insight/request-sample/2815
Increasing prevalence of urological and cardiovascular diseases fuel the global PTA balloon catheter market expansion
Increasing prevalence of urological and cardiovascular diseases is expected to increase demand for PTA balloon catheters, which in turn is expected to fuel the PTA balloon catheter market growth over the forecast period. The urological diseases include, urinary tract infections, kidney stones, and prostate problems. According to the American Cancer Society around 174,650 new cases and around 31,620 deaths occurs due to prostate cancer the U.S. in 2019. The National Institute of Diabetes and Digestive and Kidney Diseases, in 2017, reported that around 11% men and 6% women in the U.S. suffered from kidney stone.
As reported by the World Health Organization (WHO), cardiovascular diseases account for most of the non-communicable disease deaths recorded worldwide. An estimated 17.9 million deaths were registered from cardiovascular diseases in 2016, representing 31% of the global deaths. Of these deaths, 85% were due to heart attack and stroke. Therefore, increasing prevalence of non-communicable diseases is expected to increase demand for catheters, which in turn is expected to drive growth of the PTA balloon catheter market over the forecast period.
Introduction of New Products to Boost the Market Growth in North America
The major PTA balloon catheter manufacturers are deeply focused on launching new products in North America in an effort to enhance their global market share. For instance, in February 2016, Nipro North America, a division of Nipro Medical Corporation, announced the launch of Cronus HP high pressure, 0.035” over the wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. Cronus HP is indicated for percutaneous transluminal angioplasty in the femoral, popliteal, iliac, and renal arteries and for the treatment of obstructive lesions in native or synthetic arteriovenous dialysis fistulae.
Get Flat USD 2000 OFF
Buy-Now this research report: https://www.coherentmarketinsights.com/promo/buynow/2815
Reasons to Purchase this Report:
Current and future of global PTA Balloon Catheter Market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period.
The latest developments, market shares, and strategies that are employed by the major market players.
In February 2017, QT Vascular Ltd. signed an exclusive, worldwide distribution agreement with Medtronic to distribute the Chocolate PTA balloon catheter. It is currently available in the U.S. and Europe. Furthermore, in May 2015, Direct Access Medical announced that it has received the U.S. Food and Drug Administration 510(k) clearance for the full line of FirstChoice ultra high pressure (UHP) percutaneous transluminal angioplasty (PTA) 0.035-inch over the wire balloon catheters.
Significant Market Players
The renowned players operating in the global PTA balloon catheter market include Medtronic, Terumo, Cardinal Health, Boston Scientific, AndraTec, Cook Medical, Biotronik, Abbott, Creagh Medical, TriReme Medical, and Natec Medical.
Contact US:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post PTA Balloon Catheter Market to Touch US$ 2,038 Million by 2025 at a 6.8% CAGR | Generated Opportunities for Growth in the Global Small Molecule Prefilled Syringes Industry. appeared first on Gatorledger.
The article discusses the growth of the PTA Balloon Catheter market, projected to reach $2,038 million by 2025.
The increasing prevalence of cardiovascular and urological diseases is driving the demand for PTA balloon catheters.
North America and Europe are seeing significant market activity, with new product launches and distribution agreements.
Explore more articles in the Research Reports category
